By Ahmed Aboulenein WASHINGTON (Reuters) – U.S. lawmakers attempting to cut the cost of insulin for more than a million Americans to $35 per month are unlikely to succeed as November elections draw near and complicate bipartisan support, health policy and political experts say. The U.S. House of Representatives in March passed a bill capping monthly out-of-pocket insulin costs for those with health insurance at $35. Senators are drafting a wider bill that also provides incentive for drugmakers to lower list prices. Both houses must pass the same legislation for it to move forward. The Democrat…